323 related articles for article (PubMed ID: 22393089)
1. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Kuwano H
Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
[TBL] [Abstract][Full Text] [Related]
6. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer.
Lovrics PJ; Chen V; Coates G; Cornacchi SD; Goldsmith CH; Law C; Levine MN; Sanders K; Tandan VR
Ann Surg Oncol; 2004 Sep; 11(9):846-53. PubMed ID: 15313737
[TBL] [Abstract][Full Text] [Related]
8. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
[TBL] [Abstract][Full Text] [Related]
9. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
10. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C
World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
[TBL] [Abstract][Full Text] [Related]
11. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
[TBL] [Abstract][Full Text] [Related]
14. The roles of
Nakano Y; Noguchi M; Yokoi-Noguchi M; Ohno Y; Morioka E; Kosaka T; Takahashi T; Minato H
Breast Cancer; 2017 Jan; 24(1):121-127. PubMed ID: 27015862
[TBL] [Abstract][Full Text] [Related]
15. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
16. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
17. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
18. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of positron emission tomography imaging to detect lymph node metastases in patients with extramammary Paget's disease.
Fujiwara M; Suzuki T; Senoo A; Fukamizu H; Tokura Y
J Dermatol; 2017 Aug; 44(8):939-943. PubMed ID: 28295555
[TBL] [Abstract][Full Text] [Related]
20. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]